Schoormans D, et al. – Researchers examined a total of 32,757 cancer survivors and age-, gender-, and geographically matched cancer-free control participants to determine the incidence of cardiovascular disease (CVD) during a follow-up period of 1-13 years, and to explore the impact, if any, of cancer treatment, traditional cardiovascular risk factors, age, or sex on CVD incidence. Participants were adult 1-year cancer survivors without a history of CVD who were diagnosed (1999-2011) with breast, prostate, non-Hodgkin, Hodgkin, lung and trachea, basal cell carcinoma, and colorectal cancer and matched to cancer-free control participants without a history of CVD. The researchers reported an increased risk of incident CVD among prostate, and lung and trachea cancer survivors vs age-, gender- and geographically matched cancer-free control participants. Following the inclusion of traditional cardiovascular risk factors and cancer treatment information, the statistical significance of the observed increased risk among lung and trachea cancer survivors persisted. Only those who received hormones and those without traditional cardiovascular risk factors were found to have an increased risk of incident CVD among prostate cancer survivors.